Inflammatory disorders

Two new studies evaluate agents for treating ulcerative colitis

In the first clinical trial to evaluate two biologic therapies for moderate to severe ulcerative colitis (UC) head to head, Mount Sinai researchers found vedolizumab to be superior to adalimumab in a variety of measures. ...

Diseases, Conditions, Syndromes

Risk for developing idiopathic pulmonary fibrosis up in IBD

Patients with inflammatory bowel disease (IBD), especially male patients, have an increased risk for development of idiopathic pulmonary fibrosis (IPF), according to a study published online Aug. 16 in the Journal of Gastroenterology ...

Diabetes

Type 2 diabetes risk up with inflammatory bowel disease

(HealthDay)—Patients with inflammatory bowel disease (IBD) have increased risk of type 2 diabetes, according to a study published online Aug. 5 in Clinical Gastroenterology and Hepatology.

Diseases, Conditions, Syndromes

The impacts of smoking on patients with ulcerative colitis

Because smokers are less likely to develop ulcerative colitis (UC), a type of inflammatory bowel disease, patients with UC may be tempted to start smoking to lessen their symptoms. Researchers found no beneficial effects ...

Medications

FDA: blood clot, death risk up with higher dose of tofacitinib

New warnings about an increased risk of thrombosis and of death among ulcerative colitis patients taking the 10 mg twice daily dose of the drug tofacitinib (Xeljanz, Xeljanz XR) have been issued by the U.S. Food and Drug ...

page 25 from 40